[A21-165] Tofacitinib (ankylosing spondylitis) - Benefit assessment according to §35a Social Code Book V
Last updated 15.03.2022
Project no.:
A21-165
Commission:
Commission awarded on 13.12.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Muscles, bones and joints
Indication:
Adults with active ankylosing spondylitis
Result of dossier assessment:
- Patients who have responded inadequately to conventional therapy: added benefit not proven
- Patients who have had an inadequate response or intolerance to previous therapy with biological antirheumatic drugs (bDMARDs): added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A21-121 | Tofacitinib (jPsA and pJIA) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-115 | Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V (new scientific findings) | Commission completed |
| A18-52 | Tofacitinib (Colitis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-51 | Tofacitinib (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-28 | Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) | Commission completed |
| A17-18 | Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |